


Figure 1

Relevance of clinical outcomes as evaluated by participants (N = 88)



Note. ADL = Activities of daily living; MBI = Mild behavioral impairment; QoL = Quality of life.

Figure 2

Non-acceptance of adverse events of cannabidiol (CBD) as evaluated by participants (N = 88)




Figure 3

Frequency of probable discontinuation of the study depending on side effects of cannabidiol (CBD) as evaluated by participants (N = 88)

